METHOD OF PROGNOSIS OF HEMORRHAGIC COMPLICATIONS FOLLOWING CHEMOTHERAPY IN PATIENTS WITH ACUTE LEUCOSIS

FIELD: medicine; hematology. ^ SUBSTANCE: activity of glucose-6-phosphatedehydrogenase (G6PDG) and NADP-depending glutamate dehydrogenase (NADP DHG) is determined by bioluminescent test in patients with acute leucosis, before chemotherapy. When G6PDG is 10.02 to 66.51 mcU and NADP DHG is within 84.2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MANCHUK VALERIJ TIMOFEEVICH, SAVCHENKO ANDREJ ANATOL'EVICH, MOSKOV VIKTOR IVANOVICH, SMIRNOVA OL'GA VALENTINOVNA
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING PHYSICS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine; hematology. ^ SUBSTANCE: activity of glucose-6-phosphatedehydrogenase (G6PDG) and NADP-depending glutamate dehydrogenase (NADP DHG) is determined by bioluminescent test in patients with acute leucosis, before chemotherapy. When G6PDG is 10.02 to 66.51 mcU and NADP DHG is within 84.27 to 257.39 mcU, the hemorrhagic complications are predicted, and when G6PDG is 0.01 to 4.45 mcU and NADP DHG is within 0.01 to 52.86 mcU, absence of hemorrhagic complications are predicted. ^ EFFECT: method provides the increased precision of prognosis of hemorrhagic complications following chemotherapy in patients with acute leucosis. ^ 4 ex